| Sep 4 |
Spero Therapeutics to Present at Upcoming September Investor Conferences
|
| Aug 9 |
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Spero Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 6 |
TD Cowen ups Spero to buy, cites added clarity on catalyst timing
|
| Aug 6 |
Q2 2024 Spero Therapeutics Inc Earnings Call
|
| Aug 5 |
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 5 |
Spero Therapeutics GAAP EPS of -$0.33 beats by $0.05, revenue of $10.2M beats by $6.93M
|
| Jul 29 |
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
|
| Jul 8 |
3 Micro-Cap Moonshots for Fearless Investors
|
| Jun 24 |
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
|
